We have located links that may give you full text access.
English Abstract
Journal Article
Review
[Antithrombotic therapy for ischemic cerebrovascular accident].
Archives des Maladies du Coeur et des Vaisseaux 2002 November
Antithrombotic therapy should be considered in the acute phase of an ischaemic stroke in patients who are not candidates for thrombolysis. The recommended treatment is aspirin, 160 or 300 mg daily, associated in bed-ridden patients with prophylactic heparin therapy to avoid venous thromboembolic complications. Although not founded on scientific proof, high dose anticoagulants may be used instead of aspirin in special cases presumed to be at high risk of early recurrence of embolism or of extension of thrombosis. Secondary prevention in patients who have already suffered a non-embolic ischaemic stroke is based mainly on antiplatelet drugs. Aspirin, clopidogrel or the association of aspirin and dipyridamole are possible first the options. Ticlopidine is not recommended as treatment of first intention because of its secondary effects and the necessity of monitoring the blood count. Oral anticoagulants are not recommended after a non-cardio-embolic ischaemic stroke except in special cases (e.g. deficit in inhibitors of blood clotting). Secondary prevention in patients at high cardio-embolic risk (e.g. atrial fibrillation) should be based on oral anticoagulants. Cardiac disease carrying a low or uncertain risk (e.g. patent foramen ovale without an atrial septal aneurysm) is usually treated with platelet inhibitors.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app